查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球注射式給藥市場 - 2023-2030年
市場調查報告書
商品編碼
1297776

全球注射式給藥市場 - 2023-2030年

Global Injectable Drug Delivery Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

全球注射式給藥市場在2022年達到6073億美元，預計到2030年將見證有利可圖的成長，達到13641億美元。在2023-2030年的預測期間，注射給藥市場預計將呈現出10.9%的年成長率。

在某些提醒、設備的自我使用、智慧手機的連接和其他方面的幫助下，不斷創新以改善患者在注射給藥期間的體驗。此外，目前的自我注射設備，包括筆和無針注射器，已經使注射給藥變得相對容易。

注射劑是指通過注射配入人體的任何藥物。越來越多的注射劑產品的開發和批准，以及其他因素，正在推動全球注射給藥市場在預測期間的成長。

市場動態

越來越多的市場發展推動了預測期內全球注射式給藥市場的成長

越來越多的市場發展，如產品引進、產品批准、收購、合作、合併、擴張和投資等等，正在推動預測期內全球注射給藥市場的成長。

例如，2022年2月，日本跨國製藥公司武田取得了美國FDA對其TAKHZYRO（Lanadelumab-flyo）注射液單劑量預填充注射器（PFS）的授權，用於避免成人和兒童患者（12歲及以上）的遺傳性血管性水腫（HAE）的發作。

不斷成長的老年人口為全球注射給藥市場提供了前景廣闊的成長機會

腸外給藥被廣泛用於老年病人，以達到和維持治療指數較窄或口服生物利用度較差的藥物的治療濃度。因此，不斷成長的老年人口為全球市場提供了未來幾年的成長機會。

例如，根據聯合國發布的《2022年世界人口前景》，80歲或以上的人的數量預計將成長三倍，從2022年的1.57億增加到2050年的4.59億。

COVID-19影響分析

COVID-19分析包括COVID前情景、COVID情景和COVID後情景以及定價動態（包括大流行期間和之後的定價變化與COVID前情景的比較）、需求-供應譜（由於貿易限制、封鎖和後續問題造成的需求和供應的轉變）、政府計劃（政府機構為振興市場、部門或行業而採取的計劃）和製造商戰略計劃（這裡將涉及製造商為緩解COVID問題所採取的措施）。

俄烏戰爭影響分析

自俄羅斯入侵烏克蘭以來，俄烏戰爭對市場產生了負面影響，292次攻擊破壞或摧毀了218家醫院和診所，超過65次攻擊救護車，181次攻擊其他衛生基礎設施，如血液中心、牙科診所和藥店。

全球經濟衰退影響分析

在全球範圍內，不斷攀升的通貨膨脹對全球注射給藥市場產生了相當大的影響。大多數製藥公司都在觀察原料價格的上漲，並預計利潤率會下降。

醫療保健市場在非專利藥和處方藥的定價方面受到很大控制。然而，製藥公司在藥品定價方面正遇到越來越大的壓力。這種日益成長的定價壓力的主要原因是通貨膨脹率的上升對全球市場成長產生了負面影響。

人工智慧影響分析

由於產品的不斷開發，人工智慧正在對全球注射給藥市場產生積極影響。例如，一組研究人員利用谷歌的人工智慧企業DeepMind設計了一個細菌注射系統，可以將蛋白質，如殺癌藥物和基因治療，直接注入人體細胞。

目錄

第一章：方法和範圍

  • 研究方法
  • 報告的研究目標和範圍

第二章：定義和概述

第三章：執行摘要

  • 按產品類型分析
  • 按包裝分類
  • 按治療應用分類
  • 按給藥途徑分類
  • 按配銷通路分類
  • 按地區分類

第4章：動態變化

  • 影響因素
    • 驅動因素
      • 產品進步
      • 市場發展
    • 限制因素
      • 針刺傷害
      • 替代給藥系統的使用越來越多
    • 機會
    • 政府計劃
    • 影響分析

第五章：行業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 監管分析

第六章：COVID-19分析

  • COVID-19的分析
    • COVID-19之前的情況
    • COVID-19期間的情況
    • 後COVID-19及未來的情況
  • 在COVID-19期間的定價動態
  • 需求-供應譜系
  • 大流行期間與市場有關的政府計劃
  • 製造商的戰略計劃
  • 結語

第7章：俄羅斯-烏克蘭戰爭分析

第八章：全球經濟衰退分析

第九章：人工智慧影響分析

第十章：按產品類型

  • 設備
    • 傳統的注射設備
    • 自我注射裝置
    • 自動注射器
    • 筆式注射器
    • 可穿戴注射器
    • 其他設備
  • 配方
    • 傳統的給藥配方
      • 溶液
      • 重組/凍乾製劑
      • 懸浮液
      • 乳液
    • 新型藥物製劑
      • 新生物體
      • 脂質體
      • 聚合物/混合細胞
      • 微粒子

第十一章：按包裝分類

  • 小瓶
  • 安瓿
  • 瓶裝
  • 盒裝
  • 其他包裝

第十二章：按治療應用分類

  • 自身免疫性疾病
  • 激素性疾病
  • 孤兒病
  • 癌症
  • 其他治療性疾病

第13章：按給藥途徑

  • 皮內注射
  • 中樞神經系統
  • 其他途徑

第十四章：按銷售管道分類

  • 網上藥店
  • 零售藥店
  • 醫院藥店
  • 其他

第十五章：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 俄羅斯
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美其他地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 亞太其他地區
  • 中東和非洲

第16章：競爭格局

  • 競爭格局
  • 市場佔有率分析
  • 合併和收購分析

第十七章：公司簡介

  • Becton Dickinson & Company
    • 公司概述
    • 產品組合和描述
    • 財務概況
    • 主要發展情況
  • Baxter International, Inc.
  • Gerresheimer AG
  • Pfizer, Inc.
  • Schott AG
  • ELI Lilly and Company
  • Sandoz (A Division of Novartis AG)
  • Terumo Corporation
  • Teva Pharmaceutical Industries Ltd.
  • Corning Incorporated

第18章：附錄

簡介目錄
Product Code: MD799

Market Overview

The Global Injectable Drug Delivery Market reached USD 607.3 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 1,364.1 billion by 2030. The injectable drug delivery market is expected to exhibit a cagr of 10.9% during the forecast period 2023-2030.

Continuous innovations are subjected to improve patients' experience during injectable drug delivery with the help of certain reminders, the self-use of devices, connectivity of smartphones, and others. Moreover, the current self-injection devices, including pen and needle-free injectors, have made injectable drug delivery comparatively easier.

An injectable is any medication dispensed into the body via injections. The increasing number of injectable product development and approvals, among other factors, are driving the growth of the Global Injectable Drug Delivery Market during the forecast period.

Market Dynamics

The Increasing Number of Market Developments is Driving the Global Injectable Drug Delivery Market Growth in the Forecast Period

The increasing market developments, such as product introductions, product approvals, acquisitions, collaborations, mergers, expansion, and investments, among others, are driving the growth of the global injectable drug delivery market during the forecast period.

For instance, in February 2022, Takeda, a Japanese multinational pharmaceutical corporation, acquired US FDA authorization for its TAKHZYRO (lanadelumab-flyo) injection single-dose prefilled syringe (PFS) utilized to avert episodes of hereditary angioedema (HAE) in adult and pediatric patients (12 years and above).

The Growing Geriatric Population is Providing the Global Injectable Drug Delivery Market with Prospective Growth Opportunities

Parenteral drug delivery is vastly utilized for geriatrics to attain and sustain a therapeutic concentration of medications with a narrow therapeutic index or poor oral bioavailability. Thus, the growing geriatric population presents the global market with future growth opportunities in the upcoming years.

For instance, according to the World Population Prospects 2022, from the UN, the number of individuals aged 80 or above is anticipated to grow triple fold, from 157 million in 2022 to 459 million by 2050.

COVID-19 Impact Analysis

The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with Pricing Dynamics (Including pricing change during and post-pandemic comparing it to pre-COVID scenarios), Demand-Supply Spectrum (Shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), Government Initiatives (Initiatives to revive market, sector or Industry by Government Bodies) and Manufacturers Strategic Initiatives (What manufacturers did to mitigate the COVID issues will be covered here).

Russia-Ukraine War Impact Analysis

The Russia-Ukraine war has had a negative influence on the market since the Russian invasion of Ukraine with 292 attacks has damaged or destroyed 218 hospitals and clinics, over 65 attacks on ambulances, and 181 attacks on other health infrastructure, like blood centers, dental clinics, and pharmacies.

Global Recession Impact Analysis

All over the globe, climbing inflation is considerably impacting the Global Injectable Drug Delivery Market. Most pharmaceutical corporations are observing elevated prices for raw materials and are anticipating a reduction in profit margins.

The healthcare market is significantly controlled when it arrives to the pricing of generic and prescription medicines. Nevertheless, pharma corporations are encountering growing stress on drug pricing. The primary cause for this growing pricing strain is the elevated rate of inflation negatively impacting global market growth.

Artificial Intelligence Impact Analysis

Artificial intelligence is having a positive impact on the global injectable drug delivery market owing to increasing product developments. For instance, a group of investigators has harnessed Google`s AI venture DeepMind to design a bacterial injection system that can inject proteins, such as cancer-killing medicines and gene treatments, directly into human cells.

Segment Analysis

The Global Injectable Drug Delivery Market is segmented based on product type, packaging, therapeutic application, route of administration, distribution channel, and region.

The Hormonal Therapeutic Application Segment is Estimated to Hold highest Share of the Global Market.

Owing to the increasing product approvals for hormonal disorders and growing cases of hormonal disorders the hormonal therapeutic application segment is estimated to hold 30.9% of the global injectable drug delivery market.

For instance, in July 2022, European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) gave a favorable view and suggested consent for the usage of Mounjaro (tirzepatide) auto-injector pen for type 2 diabetes. Moreover, the 2022 National Diabetes Statistics Report by CDC estimated that over 130 million adults with diabetes or prediabetes in the United States.

Geographical Analysis

Europe is Estimated to Hold the Second-Largest Share of the Global Injectable Drug Delivery Market During the Forecast Period

Owing to the increasing product approvals in Europe, the region is estimated to be around 29.6% of the global injectable drug delivery market by 2030.

For instance, in February 2021, Xeris Pharmaceuticals acquired authorization from the European Commission (EC) for its Ogluo (glucagon) pre-filled pen indicated for treating extreme hypoglycemia in children, adults, and adolescents aged 2 years and over with diabetes mellitus.

Competitive Landscape

The major global players in the market include: Becton Dickinson & Company, Baxter International, Inc., Gerresheimer AG, Pfizer, Inc., Schott AG, Eli Lilly and Company, Sandoz, Terumo Corporation, Teva Pharmaceutical Industries Ltd, Corning Incorporated, among others.

Why Purchase the Report?

  • To visualize the Global Injectable Drug Delivery Market segmentation based on product type, packaging, therapeutic application, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous injectable drug delivery market-level data points with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The Global Injectable Drug Delivery Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Packaging
  • 3.3. Snippet by Therapeutic Application
  • 3.4. Snippet by Route of Administration
  • 3.5. Snippet by Distribution Channel
  • 3.6. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Product Advancements
      • 4.1.1.2. Market Developments
    • 4.1.2. Restraints
      • 4.1.2.1. Needle Stick injuries
      • 4.1.2.2. The Increasing Use of Alternative Drug Delivery Systems
    • 4.1.3. Opportunity
    • 4.1.4. Government Initiatives
    • 4.1.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Post COVID-19 & Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Global Recession Analysis

9. Artificial Intelligence Impact Analysis

10. By Product Type

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.1.2. Market Attractiveness Index, By Product Type
  • 10.2. Devices
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 10.2.3. Conventional injection devices
    • 10.2.4. Self-injection devices
    • 10.2.5. Autoinjectors
    • 10.2.6. Pen Injectors
    • 10.2.7. Wearable injectors
    • 10.2.8. Other devices
  • 10.3. Formulations
    • 10.3.1. Conventional drug delivery formulation
      • 10.3.1.1. Solutions
      • 10.3.1.2. Reconstituted/Lyophilized Formulations
      • 10.3.1.3. Suspensions
      • 10.3.1.4. Emulsions
    • 10.3.2. Novel drug formulations
      • 10.3.2.1. Niosomes
      • 10.3.2.2. Liposomes
      • 10.3.2.3. Polymeric/mixed cells
      • 10.3.2.4. Microparticles

11. By Packaging

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Packaging
    • 11.1.2. Market Attractiveness Index, By Packaging
  • 11.2. Vials*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Ampule
  • 11.4. Bottle
  • 11.5. Cartridges
  • 11.6. Others

12. By Therapeutic Application

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
    • 12.1.2. Market Attractiveness Index, By Therapeutic Application
  • 12.2. Autoimmune Disease
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Hormonal Disorders
  • 12.4. Orphan disease
  • 12.5. Cancer
  • 12.6. Other therapeutic diseases

13. By Route of Administration

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.1.2. Market Attractiveness Index, By Route of Administration
  • 13.2. Intradermal
    • 13.2.1. Introduction
    • 13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 13.3. Central Nervous System
  • 13.4. Others

14. By Distribution Channel

  • 14.1. Introduction
    • 14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 14.1.2. Market Attractiveness Index, By Distribution Channel
  • 14.2. Online Pharmacies
    • 14.2.1. Introduction
    • 14.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 14.3. Retail pharmacies
  • 14.4. Hospital Pharmacies
  • 14.5. Others

15. By Region

  • 15.1. Introduction
    • 15.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 15.1.2. Market Attractiveness Index, By Region
  • 15.2. North America
    • 15.2.1. Introduction
    • 15.2.2. Key Region-Specific Dynamics
    • 15.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 15.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Packaging
    • 15.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic application
    • 15.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 15.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 15.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 15.2.8.1. The U.S.
      • 15.2.8.2. Canada
      • 15.2.8.3. Mexico
  • 15.3. Europe
    • 15.3.1. Introduction
    • 15.3.2. Key Region-Specific Dynamics
    • 15.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 15.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Packaging
    • 15.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic application
    • 15.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 15.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 15.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 15.3.8.1. Germany
      • 15.3.8.2. The U.K.
      • 15.3.8.3. France
      • 15.3.8.4. Italy
      • 15.3.8.5. Russia
      • 15.3.8.6. Rest of Europe
  • 15.4. South America
    • 15.4.1. Introduction
    • 15.4.2. Key Region-Specific Dynamics
    • 15.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 15.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Packaging
    • 15.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic application
    • 15.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 15.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 15.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 15.4.8.1. Brazil
      • 15.4.8.2. Argentina
      • 15.4.8.3. Rest of South America
  • 15.5. Asia-Pacific
    • 15.5.1. Introduction
    • 15.5.2. Key Region-Specific Dynamics
    • 15.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 15.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Packaging
    • 15.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic application
    • 15.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 15.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 15.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 15.5.8.1. China
      • 15.5.8.2. India
      • 15.5.8.3. Japan
      • 15.5.8.4. Australia
      • 15.5.8.5. Rest of Asia-Pacific
  • 15.6. Middle East and Africa
    • 15.6.1. Introduction
    • 15.6.2. Key Region-Specific Dynamics
    • 15.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 15.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Packaging
    • 15.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic application
    • 15.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 15.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

16. Competitive Landscape

  • 16.1. Competitive Scenario
  • 16.2. Market Share Analysis
  • 16.3. Mergers and Acquisitions Analysis

17. Company Profiles

  • 17.1. Becton Dickinson & Company
    • 17.1.1. Company Overview
    • 17.1.2. Product Portfolio and Description
    • 17.1.3. Financial Overview
    • 17.1.4. Key Developments
  • 17.2. Baxter International, Inc.
  • 17.3. Gerresheimer AG
  • 17.4. Pfizer, Inc.
  • 17.5. Schott AG
  • 17.6. ELI Lilly and Company
  • 17.7. Sandoz (A Division of Novartis AG)
  • 17.8. Terumo Corporation
  • 17.9. Teva Pharmaceutical Industries Ltd.
  • 17.10. Corning Incorporated

LIST NOT EXHAUSTIVE

18. Appendix

  • 18.1. About Us and Services
  • 18.2. Contact Us